IL160620A0 - Combinations comprising cox-2 inhibitors and aspirin - Google Patents
Combinations comprising cox-2 inhibitors and aspirinInfo
- Publication number
- IL160620A0 IL160620A0 IL16062002A IL16062002A IL160620A0 IL 160620 A0 IL160620 A0 IL 160620A0 IL 16062002 A IL16062002 A IL 16062002A IL 16062002 A IL16062002 A IL 16062002A IL 160620 A0 IL160620 A0 IL 160620A0
- Authority
- IL
- Israel
- Prior art keywords
- aspirin
- cox
- inhibitors
- combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0124459.9A GB0124459D0 (en) | 2001-10-11 | 2001-10-11 | Organic compounds |
PCT/EP2002/011380 WO2003033001A1 (en) | 2001-10-11 | 2002-10-10 | Combinations comprising cox-2 inhibitors and aspirin |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160620A0 true IL160620A0 (en) | 2004-07-25 |
Family
ID=9923664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16062002A IL160620A0 (en) | 2001-10-11 | 2002-10-10 | Combinations comprising cox-2 inhibitors and aspirin |
Country Status (19)
Country | Link |
---|---|
US (2) | US20040235802A1 (ru) |
EP (1) | EP1435968A1 (ru) |
JP (1) | JP2005505606A (ru) |
KR (1) | KR20040044891A (ru) |
CN (1) | CN1625405A (ru) |
AU (1) | AU2006249254A1 (ru) |
BR (1) | BR0213181A (ru) |
CA (1) | CA2458981A1 (ru) |
CO (1) | CO5570661A2 (ru) |
GB (1) | GB0124459D0 (ru) |
HU (1) | HUP0401854A2 (ru) |
IL (1) | IL160620A0 (ru) |
MX (1) | MXPA04003365A (ru) |
NO (1) | NO20041432L (ru) |
NZ (1) | NZ532158A (ru) |
PL (1) | PL369005A1 (ru) |
RU (1) | RU2004114560A (ru) |
WO (1) | WO2003033001A1 (ru) |
ZA (1) | ZA200401302B (ru) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
US7338971B2 (en) * | 2001-08-30 | 2008-03-04 | El-Naggar Mawaheb M | Treatment of inflammatory, cancer, and thrombosis disorders |
IL164222A0 (en) | 2002-04-09 | 2005-12-18 | Flamel Tech Sa | Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) |
CA2487414A1 (en) | 2002-06-11 | 2003-12-18 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
AU2005206227A1 (en) * | 2004-01-27 | 2005-08-04 | Merck Frosst Company | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
CA2609618C (en) * | 2005-05-24 | 2016-01-05 | Flamel Technologies | Novel acetylsalicylic acid formulations |
CN101257800B (zh) * | 2005-07-18 | 2012-07-18 | 好利用医疗公司 | 包含法莫替丁和布洛芬的药物 |
US20080020040A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Unit dose form for administration of ibuprofen |
US20080021078A1 (en) * | 2006-07-18 | 2008-01-24 | Horizon Therapeutics, Inc. | Methods and medicaments for administration of ibuprofen |
US8067451B2 (en) | 2006-07-18 | 2011-11-29 | Horizon Pharma Usa, Inc. | Methods and medicaments for administration of ibuprofen |
US8067033B2 (en) | 2007-11-30 | 2011-11-29 | Horizon Pharma Usa, Inc. | Stable compositions of famotidine and ibuprofen |
EP2063873A2 (en) * | 2006-08-31 | 2009-06-03 | Horizon Therapeutics, Inc. | Nsaid dose unit formulations with h2-receptor antagonists and methods of use |
US9757529B2 (en) * | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
CN104173359B (zh) * | 2014-09-05 | 2017-05-03 | 罗国安 | 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用 |
WO2018167447A1 (en) * | 2017-03-14 | 2018-09-20 | University Of Sheffield | Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants |
US10272107B2 (en) * | 2017-09-05 | 2019-04-30 | Kenneth O. Russell | Method for treating inflammatory brain disorders and traumatic brain injury |
US10586872B2 (en) * | 2018-07-03 | 2020-03-10 | International Business Machines Corporation | Formation of wrap-around-contact to reduce contact resistivity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4743596A (en) * | 1987-06-16 | 1988-05-10 | Lapin Alfred R | Anti-arthritic preparation |
CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
PL351069A1 (en) * | 1999-12-08 | 2003-03-10 | Pharmacia Corp | Valdecoxib compositions |
GB0002336D0 (en) * | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
WO2002017896A2 (en) * | 2000-08-29 | 2002-03-07 | Peter Van Patten | Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid |
-
2001
- 2001-10-11 GB GBGB0124459.9A patent/GB0124459D0/en not_active Ceased
-
2002
- 2002-10-10 JP JP2003535804A patent/JP2005505606A/ja active Pending
- 2002-10-10 MX MXPA04003365A patent/MXPA04003365A/es unknown
- 2002-10-10 CA CA002458981A patent/CA2458981A1/en not_active Abandoned
- 2002-10-10 HU HU0401854A patent/HUP0401854A2/hu unknown
- 2002-10-10 WO PCT/EP2002/011380 patent/WO2003033001A1/en not_active Application Discontinuation
- 2002-10-10 IL IL16062002A patent/IL160620A0/xx unknown
- 2002-10-10 NZ NZ532158A patent/NZ532158A/en unknown
- 2002-10-10 EP EP02779476A patent/EP1435968A1/en not_active Withdrawn
- 2002-10-10 BR BR0213181-1A patent/BR0213181A/pt not_active IP Right Cessation
- 2002-10-10 PL PL02369005A patent/PL369005A1/xx not_active Application Discontinuation
- 2002-10-10 RU RU2004114560/15A patent/RU2004114560A/ru not_active Application Discontinuation
- 2002-10-10 KR KR10-2004-7003586A patent/KR20040044891A/ko not_active Application Discontinuation
- 2002-10-10 US US10/487,759 patent/US20040235802A1/en not_active Abandoned
- 2002-10-10 CN CNA028200853A patent/CN1625405A/zh active Pending
-
2004
- 2004-02-18 ZA ZA200401302A patent/ZA200401302B/xx unknown
- 2004-04-05 NO NO20041432A patent/NO20041432L/no not_active Application Discontinuation
- 2004-04-15 CO CO04034535A patent/CO5570661A2/es not_active Application Discontinuation
-
2006
- 2006-12-08 AU AU2006249254A patent/AU2006249254A1/en not_active Abandoned
-
2007
- 2007-08-07 US US11/834,748 patent/US20080027032A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1625405A (zh) | 2005-06-08 |
US20040235802A1 (en) | 2004-11-25 |
AU2006249254A1 (en) | 2007-01-04 |
CO5570661A2 (es) | 2005-10-31 |
NZ532158A (en) | 2006-04-28 |
NO20041432L (no) | 2004-06-28 |
EP1435968A1 (en) | 2004-07-14 |
NO20041432D0 (no) | 2004-04-05 |
US20080027032A1 (en) | 2008-01-31 |
HUP0401854A2 (hu) | 2004-12-28 |
PL369005A1 (en) | 2005-04-18 |
MXPA04003365A (es) | 2004-07-23 |
RU2004114560A (ru) | 2005-05-20 |
JP2005505606A (ja) | 2005-02-24 |
WO2003033001A1 (en) | 2003-04-24 |
GB0124459D0 (en) | 2001-12-05 |
CA2458981A1 (en) | 2003-04-24 |
KR20040044891A (ko) | 2004-05-31 |
ZA200401302B (en) | 2005-01-04 |
BR0213181A (pt) | 2004-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1061851A1 (en) | Gyrase inhibitors and uses thereof | |
HK1053984B (zh) | 回旋酶抑制劑及其用途 | |
EP1423120A4 (en) | 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF | |
PL374598A1 (en) | Caspase inhibitors and uses thereof | |
IL172752A0 (en) | Cox-2 and faah inhibitors | |
IL160620A0 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
EP1435989A4 (en) | INHIBITORS AND LIGANDS OF PTP1B | |
AU2002361861A8 (en) | Selective 11beta-hsd inhibitors and methods for use thereof | |
AU4217201A (en) | Tri-aryl-substituted-ethane pde4 inhibitors | |
GB0114014D0 (en) | Compostion and use | |
EP1434772A4 (en) | CONNECTIONS AND METHODS | |
GB2376073B (en) | Fluid-gauging systems and methods | |
GB0229834D0 (en) | Target and method | |
PL363544A1 (en) | Piperazino-derivatives and their use as pde4 inhibitor | |
AU2001232809A1 (en) | Gyrase inhibitors and uses thereof | |
GB2382598B (en) | Construction and elongate members therefor | |
ZA200306331B (en) | Piperazinylcarbonylquinolines and isoquinolines | |
EP1379240A4 (en) | CONNECTIONS AND METHODS | |
EP1367123A4 (en) | NEUROTONIN AND ITS USE | |
GB0220776D0 (en) | FOXP2 and uses thereof | |
AU2003267790A8 (en) | Lipase inhibitors and uses thereof | |
GB0109278D0 (en) | Enzyme inhibitors | |
GB0106063D0 (en) | Libraries and their use | |
AU2002363187A1 (en) | Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors | |
AU2002223649A1 (en) | Vegh inhibitors and their use |